Christoph Lengauer, Ph.D.

Christoph Lengauer, Ph.D.

Venture Partner, Third Rock Ventures
President, Celsius Therapeutics
Adjunct Associate Professor of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine
Faculty Associate of the Program for Evolutionary Dynamics, Harvard University

Christoph is a Venture Partner at Third Rock Ventures, where he helps discover, launch and build companies that boldly merge science, strategy, business and medicine. At Celsius, he leads the company and mentors its members.

Christoph has a proven record in drug discovery, including contributing to more than 25 drugs that reached human clinical trials and four approved lifesaving medicines. In his previous role as Chief Scientific Officer at Blueprint Medicines, Christoph helped discover and develop BLU-285, a breakthrough therapy for patients with gastrointestinal stromal tumors and systemic mastocytosis, BLU-554 for patients with hepatocellular carcinoma, and BLU-667 for patients with thyroid and non-small cell lung cancer.

Prior to joining the biotechnology industry, Christoph worked for more than a decade with Drs. Bert Vogelstein and Kenneth Kinzler at the Sidney Kimmel Comprehensive Cancer Center at the Johns Hopkins University School of Medicine in Baltimore, MD. Christoph discovered that all cancers are genetically unstable, which explains their genetic heterogeneity and drug resistance.

Christoph is a strong and outspoken advocate of patients’ rights and is featured in the New York Times best seller and HBO movie The Immortal Life of Henrietta Lacks.